In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

RNAi company Dicerna Pharmaceuticals nets $96.3mm in IPO

Executive Summary

Five months after raising $60mm in Series C funds from its venture backers, Dicerna Pharmaceuticals Inc. (gene silencing in rare liver diseases and genetically defined cancers) netted $96.3mm in its initial public offering of 6.9mm shares (including the overallotment) for $15. Earlier in the month, the company planned to sell 5mm shares at $11-13, and then upped the proposed price to $14.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register